Alle Publikationen

Filtern Sie das Suchergebnis:

Alle Vortrag Poster Abstract Fullpaper

Ihr Suchergebnis:

(1) Schöndorf T., Lübben G., Forst T., Köder C., Roth W., Hohberg C., Löbig M., Pfützner A.
Relaxin expression correlates with serum VEGF in male patients with type 2 diabetes receiving oral antidiabetic treatment. 66th Scientific Sessions of the American Diabetes Association, Washington, June 9-13, 2006
Diabetes 55(Suppl.1), A715 (2006)
(Abstract)

(2) Pfützner A., Pfützner A.H., Stridde E., Huppertz H. von Törne I., Forst T., Petrak F.
Laboratory risk marker characteristics of insufficiently controlled patients with type 2 diabetes requiring insulin therapy. 66th Scientific Sessions of the American Diabetes Association, Washington, June 9-13, 2006
Diabetes 55(Suppl.1), A531 (2006)
(Abstract)

(3) Hohberg C., Lübben G., Pfützner A., Roth W., Konrad T., Karagiannis E., Forst T.
Conversion of type 2 diabetic patients treated with a conventional insulin regimen to oral treatment with pioglitazone and glimepiride improves insulin resistance and does not result in an overall deterioration of metabolic control. 66th Scientific Sessio
Diabetes 55(Suppl.1), Washington, June 9-13, 2006, A481 (2006)
(Abstract)

(4) Pfützner A., Hohberg C., Borchert M., Roth W., Lübben G., Konrad T., Forst T.
Switching from insulin therapy to pioglitazone: impact on glucose control, ß-cell function and cardiovascular risk. 66th Scientific Sessions of the American Diabetes Association, Washington, June 9-13, 2006
Diabetes 55(Suppl.1), A480 (2006)
(Abstract)

(5) Pfützner A., Butzer R., Borchert M., Möller M., Hohberg C., Grenningloh M., Lübben G., Forst T.
Impairment of ß-Cell Secretion after Glucagon Stimulation in Insulin-treated Patients with Type 2 Diabetes is Associated With an Increase in Fasting Intact Proinsulin Concentrations. 65th Scientific Sessions of the American Diabetes Association, San Diego
Diabetes 54(Suppl.1), A633 (2005)
(Abstract)

(6) Pahler S., Pfützner A., Nguyen M., Lübben G., Grabellus M., Roth W., Gottschall V., Forst T.
IRIS III-Study: Pioglitazone Improves Metabolic Control and Blood Pressure in Patients with Type 2 Diabetes without Increase in Body Weight. 65th Scientific Sessions of the American Diabetes Association, San Diego, June 2005
Diabetes 54(Suppl.1), A527 (2005)
(Abstract)

(7) Jensterle M., Janez A., Weber M., Kocijancic A., Forst T., Pfützner A.
Assessment of Insulin Resistance in Patients with Polycystic Ovary Syndrome. 65th Scientific Sessions of the American Diabetes Association, San Diego, June 2005
Diabetes 54(Suppl.1), A526 (2005)
(Abstract)

(8) Forst T., Pfützner A., Forst S., Larbig M., Dewarrat R., Schrepfer T., Caduff A.
Accuracy of the Non-Invasive Glucose Monitoring Device Pendra® compared to Alternate Site Glucose Measurements at the Lower Forearm during Dynamic Blood Glucose Changes in Type 1 Diabetic Patients.64th Scientific Sessions of the American Diabetes Associat
Diabetes 53(Suppl.1), A102 (2004)
(Abstract)

(9) Forst T., Nguyen M., Langenfeld M., Friedrich Ch., Lübben G., Fennenkötter U., Kann P., Pfützner A.
Effects of Pioglitzone and Glimepiride on Microvascular Function in Patients with Diabetes Mellitus Type 2. 64th Scientific Sessions of the American Diabetes Association, Orlando June4th-8th
Diabetes 53(Suppl.1), A308 (2004)
(Abstract)

(10) Grundler S., Weise A., Haller C., Forst T., Pfützner A.
Genotyping of metabolic enzymes participating in drug-metabolism for Type 2 Diabetics and Non-Diabetics. 64th Scientific Sessions of the American Diabetes Association, Orlando June4th-8th
Diabetes 53(Suppl.1) , A540 (2004)
(Abstract)

(11) Pfützner A., Standl E., Schulze J., Pahler S., Larbig M., Lübben G., Forst T.
Results from the IRIS-II study: intact proinsulin from the pancreatic ß-cell is a specific marker for insulin resistance. 63rd Scientific Sessions of the American Diabetes Association, New Orleans June13th-17th
Diabetes 52(Suppl.1), A542 (2003)
(Abstract)

(12) Steiner S., Pfützner A., Heinemann L., Löbig M., Heise T., Forst T.
Intact but not total proinsulin predicts the successful imitation of first phase insulin release in patients with type 2 diabetes. 63rd Scientific Sessions of the American Diabetes Association, New Orleans June13th-17th
Diabetes 52(Suppl.1), A544 (2003)
(Abstract)

(13) Hohberg C., Kunt T., Löbig M., Forst T., Pfützner A.
Evaluation of human resistin ELISAs with serum from patients with type 2 diabetes and different degrees of insulin resistance. 63rd Scientific Sessions of the American Diabetes Association, New Orleans June13th-17th
Diabetes 52(Suppl.1), A539 (2003)
(Abstract)

(14) Hohberg C., Forst T., Konrad T., Jung S., Strotmann I., Forst S., Lübben G., Pfützner A.
Evaluation of several clinical insulion resistance scores by an intravenous glucose tolerance test in type 2 diabetic patients. 63rd Scientific Sessions of the American Diabetes Association, New Orleans June13th-17th
Diabetes 52(Suppl.1), A460 (2003)
(Abstract)

(15) Forst T, Hohberg C, Mondok A, Pahler S, Konrad T, Lübben G, Pfützner A.
: Fasting intact Proinsulin is a highly specific indicator of Insulin Resistance in Type 2 Diabetes. 63rd Scientific Sessions of the American Diabetes Association, New Orleans June13th-17th
Diabetes 52(Suppl.1), A459 (2003)
(Abstract)

(16) Lindner A., Forst T., Mondok A., Caduff A., Buschor S., Schrepfer A., Pfützner A.
Stability of NI-CGMD non-invasive blood glucose monitoring during changes in microvascular skin blood flow. 63rd Scientific Sessions of the American Diabetes Association, New Orleans June13th-17th
Diabetes 52(Suppl.1), A435 (2003)
(Abstract)

(17) Forst T., Kunt T., Pohlmann T., Goitom K., Löbig M., Beyer J., Pfützner A.
Microvascular Skin Blood Flow During a 75g Oral Glucose Load in Healthy Individuals, 58th Scientific Sessions of the American Diabetes Association, Chicago, June 13 – 16, 1998
Diabetes, 47 (Suppl.1), A407 (1998)
(Abstract)

(18) Pfützner A., Lindner U., Trautmann M., Duran G., Herschbach.
Insulin Lispro and Quality of Life – Results from the German QoL Study, 58th Scientific Sessions of the American Diabetes Association, Chicago, June 13 – 16, 1998
Diabetes, 47 (Suppl.1), A354 (1998)
(Abstract)

(19) Pfützner A., Gudat U., Trautmann M.E.
Longterm Use of Insulin Lispro in Intensive Insulin Treatment, 56th Annual Meeting, Am. Diab. Assoc., San Francisco, USA, 8.-11. Juni 1996
Diabetes, 45 (Suppl.2), 284A (1996)
(Abstract)